These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18091052)

  • 21. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy.
    van Roermund JG; Hinnen KA; Battermann JJ; Witjes JA; Bosch JL; Kiemeney LA; van Vulpen M
    BJU Int; 2010 Jan; 105(1):42-8. PubMed ID: 19519759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
    Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
    Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    Palma D; Pickles T; Tyldesley S;
    BJU Int; 2007 Aug; 100(2):315-9. PubMed ID: 17617138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience.
    Sylvester JE; Grimm PD; Wong J; Galbreath RW; Merrick G; Blasko JC
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):376-81. PubMed ID: 20864269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic?
    Bittner N; Merrick GS; Butler WM; Galbreath RW; Adamovich E; Wallner KE
    Brachytherapy; 2013; 12(1):14-8. PubMed ID: 22884256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience.
    Hsu CY; Joniau S; Oyen R; Roskams T; Van Poppel H
    Eur Urol; 2007 Jan; 51(1):121-8; discussion 128-9. PubMed ID: 16797831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
    Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy.
    Taira AV; Merrick GS; Galbreath RW; Butler WM; Lief JH; Wallner KE
    BJU Int; 2010 Sep; 106(6):809-14. PubMed ID: 20201830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
    Vargas CE; Martinez AA; Boike TP; Spencer W; Goldstein N; Gustafson GS; Krauss DJ; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):416-23. PubMed ID: 16879929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW
    Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disease-specific survival following the brachytherapy management of prostate cancer.
    Stock RG; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):810-6. PubMed ID: 16309852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes in younger men following permanent prostate brachytherapy.
    Shapiro EY; Rais-Bahrami S; Morgenstern C; Napolitano B; Richstone L; Potters L
    J Urol; 2009 Apr; 181(4):1665-71; discussion 1671. PubMed ID: 19233394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
    Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.